P271: Long-term vosoritide improves bone mineral density and bone content in children with achondroplasia: Results from quantitative computed tomography analyses
Abstract
Vosoritide, a C-type natriuretic peptide analogue that stimulates endochondral bone growth, is the only approved precision therapy for children with achondroplasia (ACH). The ongoing CANOPY ACH clinical program has over a decade of longitudinal data demonstrating that vosoritide is well tolerated and causes significant, sustained improvements in annualized growth velocity. The effect of long-term vosoritide use on bone has not been investigated. We used peripheral quantitative computed tomography (QCT) imaging to assess bone growth parameters in children with ACH using vosoritide long-term.
Fields of Study & Subjects
Connective tissue disorders research
Growth Hormone and Insulin-like Growth Factors
Bone health and osteoporosis research
Publication details
- Journal / source
- Genetics in Medicine Open
- Volume
- 4
- Pages
- 103765–103765
- Publication date
- 1 January 2026
- Language
- EN